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Peptides in solution currently exist under several conformations; an equilibrium which varies with solvent polarity. Despite or because of this
structure versatility, peptides can be selective biological tools: they can adapt to a target, vary conformation with solvents and so on. These
capacities are crucial for cargo carriers. One promising way of using peptides in biotechnologies is to decipher their medium–sequence–
structure–function relationships and one approach is molecular modelling. Only few ‘‘in silico’’ methods of peptide design are described in the
literature. Most are used in support of experimental screening of peptide libraries. However, the way they are made does not teach us much for
future researches. In this paper, we describe an ‘‘in silico’’ method (PepDesign) which starts by analysing the native interaction of a peptide with a
target molecule in order to define which points are important. From there, a modelling protocol for the design of Fbetter_ peptides is set. The
PepDesign procedure calculates new peptides fulfilling the hypothesis, tests the conformational space of these peptides in interaction with the
target by angular dynamics and goes up to the selection of the best peptide based on the analysis of complex structure properties. Experimental
biological assays are finally used to test the selected peptides, hence to validate the approach. Applications of PepDesign are wide because the
procedure will remain similar irrespective of the target which can be a protein, a drug or a nucleic acid. In this paper, we describe the design of
peptides which binds to the fusogenic helical form of the C-terminal domain of the Ah peptide (Ah29–42).
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Despite the promising future of peptides in drug discovery,
few methods of rational design of peptides are described in
the literature. Several groups made peptides which inhibit a
target protein with high affinity. They used peptide libraries
expressed in phages or synthesized by solid-phase. Notably,
Kasher et al. [1] and Katchalski et al. [2] designed peptides
with a high affinity for a-Bungarotoxin (a-BTX), a toxic
snake neurotoxin; these peptides inhibit the a-BTX binding to
acetylcholine receptor (AchR) at the neuromuscular junction.
They proposed a general approach named ‘‘systematic residue
replacement’’ (SRR): they screened peptide libraries to
identify a lead, characterized its interaction with the target
by NMR or X-ray and performed a restricted SRR of the lead
using residues categorized into 6 groups according to their
physico-chemical properties. This method gave very good
results but requires numerous biological assays in order to
select the best peptides.
Other groups used molecular dynamics in order to simulate
the interaction of a peptide with a target. Yang et al. [3] designed
a peptide which had potential bioactivity to antagonize the
function of human interleukin-6 (hIL-6) using molecular
modelling and molecular dynamics trajectory analysis. How-
ever, due to the time required for molecular dynamics
calculation, this method allows to test only few peptides.
We developed an ‘‘in silico’’ method named ‘‘PepDesign’’
to propose peptides with selected binding patterns. In this
paper we used the method to make a binding partner to the
helical form of Ah29–42 peptide. By analogy to the SSR
method, new peptides are designed by residue substitution
of a template. The procedure is automatic up to the selection
of molecules with improved interaction with the target.
Experimental assays come as the validation and quantifica-
tion of the peptide quality.
Ah29–42 is implicated in the formation of senile plaques
of Alzheimer’s disease [4–6]. The peptide is known to have
several conformations, from random coil to helix and to
beta-extended forms. Because of its high hydrophobicity, the
latter is responsible for the peptide aggregation often
observed in NMR experiments. Beta aggregates are consid-
ered as a denaturated stable structural conformation. Before
the peptide is aggregating, a transient helical form might
have peculiar biological properties because of its hydropho-bicity profile [7]. It should be a tilted peptide like the
helical conformations of the N-terminal fragments of fusion
proteins of several viruses such as SIV (Simian Immunode-
ficiency Virus) [8] or BLV (Bovine Leukaemia Virus) [9].
Tilted peptides are short fragments (10–20 residues) with an
asymmetric hydrophobicity gradient along their helix axis.
Their mean hydrophobicity leads them to insert into
membranes and the assymmetric profile of this hydropho-
bicity allows them to insert tilted with an angle ranging
from 30- to 60- with respect to the membrane surface. The
tilted orientation is thought to destabilize membranes and to
induce processes such as fusion [7]. The Ah29–42 peptide
induces liposome fusion in relation with its helix hydro-
phobicity properties [10].
A relationship exists between the type of ApoE ((2, (3
and (4) allele in human and the risks to develop the
Alzheimer’s disease. For a while, the debate was whether
the (2 and (3 allele of ApoE prevented from, or whether the
(4 allele was a risk factor for the Alzheimer’s disease. We
supported that the (2 and (3 alleles prevent the disease
because we found that their C-terminal parts interact
specifically with the C-terminal domain of the amyloid
peptide. Interestingly, this interaction partially inhibited
Ah29–42 fusogenic properties on liposomes in vitro [11].
In contrast, the (4 allele of apolipoprotein E as well as
fragments of apolipoprotein A1 failed to inhibit the amyloid
peptide fusogenic properties supporting the specificity of the
(2 and (3 apolipoprotein effects [11–13]. It was then
demonstrated that the 200–299 fragment of ApoE can have
a direct interaction with the C-part of Ah in vitro [11].
Parallely, Lins et al. [14] studied the ApoE–Ah interaction
by molecular modelling and suggested that the minimal
binding site of apolipoprotein E was in its helix 270–287.
Using the ‘‘in silico’’ PepDesign method, we attempted the
rational design of complement peptides to Ah29–42 by taking
the ApoE270–287 fragment as a lead and looking for an
improved stability of its interaction with Ah. First, we
reproduced the complex described by Lins et al. [14] and
identified the key-residues of interaction. Mutant peptides were
then generated by residue substitution. Energies of interaction
of mutants with Ah29–42 were computed. We selected
peptides likely to show a stronger interaction with Ah29–42
than the native apolipoprotein peptide and analysed the reasons
for the improvement. Mainly two classes of mutants were
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sible for a better pairing with the Ah29–42 peptide, another in
which hydrophobicity was the main responsible. One peptide
of each class was synthesized.
We used the self-ability of Ah29–42 to induce fusion of
liposomes to compare the native ApoE270–287 and the mutant
peptides capacities to inhibit this capacity. We assumed that the
best the inhibition of fusion, the best the interaction.
Experimental inhibition of lipid fusion monitored by fluores-
cence spectroscopy (fusion of lipid phases and leakage) is in
agreement with our calculations emphasizing that it is possible
to design peptides whose interactions with Ah29–42 are
stronger than those of the native ApoE270–287 fragment,
validating the ‘‘in silico’’ approach.
2. Materials and methods
2.1. In silico
2.1.1. Peptides
Helical peptides (ApoE270–287 and Ah29–42) were constructed using
Hyperchem (release 6.1 for windows-Hypercube) assigning values of phi/psi
angles of 58- and 47- corresponding to classical alpha-helical structure
[15]. The conformation of backbone and side chains was optimised by a
steepest descent procedure completed by a conjugated gradient procedure.
2.1.2. ApoE/Ab complex
The hypermatrix procedure, derived from the method allowing to surround
a drug with lipids [16] was used to build the ApoE270–287/Ah29–42
complex. The Ah29–42 helix was maintained still while the ApoE270–287
alpha helix moved around with five degrees of freedom (36 rotations around
Ah29–42, 36 self-rotations by steps of 10-, 10 translations perpendicular and
parallel to the Ah helix axis by steps of 1 and 0.5 A˚, respectively, and 20 tilts of
1- with respect to the Ah helix axis). During the procedure, 2.6106 relative
positions of the two peptides were explored. For each position, the energy of
interaction was calculated as the sum of Coulomb, Van der Waals and solvation
energies. The complex exhibiting the best gain of energy was kept.
2.1.3. Key positions for substitution of ApoE
In order to determine residues of the ApoE270–287 helix in interaction
with Ah, we first optimised the hypermatrix complex by an angular Monte
Carlo procedure as described later. Then, we compared the accessible surface
area (ASA) of each ApoE and Ah residue in the complex and in the isolated
molecules, analysed the atoms in interaction, their distance, the energy of
interaction, etc [17–19]. From there, we defined which residues and what kinds
of interaction were involved in the ApoE270–287/Ah29–42 interaction.
Results were used to select residues for substitution.
2.1.4. Generation of ApoE mutants
To generate mutants of the ApoE270–287 peptide, we used the complex of
ApoE270–287 and Ah29–42 helix structures obtained after the hypermatrix
procedure as a template. This complex was loose enough to allow residue
substitutions without generating harsh steric clashes. All key positions amino
acids of the wild type ApoE peptide in interaction with Ah in the complex were
open to substitutions generating 1024 possible peptides by random combination
of substitutions.
The energy of each mutant/Ah complex was minimized by an angular Monte
Carlo procedure based on the angular dynamics previously described [20]. This
procedure differs from a current energy minimization on several points: valence
angles and bond lengths are maintained constant, atom movements are rotations
around molecule torsion axes and rotation movements are propagated along the
chain; finally, energy of atomic interactions is distributed on rotation axes, and
every axis is independently minimized resulting in a local rather than a global
energy minimization. During the procedure, one molecule remains still and the
other moves around and along. The twomolecules move their side chains and the
mutant also adapts its backbone architecture. Energy of interaction is minimizedat 25 -C for 200 steps of Monte Carlo procedure, each step allowing a maximal
3D translation of 0.25A of the movingmolecule centre and amaximal tilt of 1- of
its axis. At each step, 7 successive rotations of all axes at 25 -C optimised the side
chain structures. The energy of the system is the sum of intra and intermolecular
energies of non-bound interactions: for the intramolecular interaction Van der
Waals (using Levitt description of soft-atomwith 1000 kcal/mol as a limit energy
value [21] and electrostatic energy (Coulomb) were summed; for the
intermolecular interactions, Van der Waals (Levitt description of soft-atom with
100 kcal as a limit energy value), Coulomb (with a sigmoid description of (
variation and FCPAC atomic charges [22] and, two terms of hydrophobicity (i.e.
due to peptide–peptide interactions and to water/peptide interaction [20] were
calculated. The first selection step of peptide/Ah29–42 complexes is at that point
on minimal total energy (internal and external atomic interactions).
2.1.5. Complex analysis and final selection
Complexes were characterized by their energy patterns: the residue Mean
Force potential was calculated from atomic mean force potential scale [23].
Scale for atomic Mean Force Potential values (MFP) was prepared by
computing all atomic interactions in of 500 3D structures [24]. The equation
of Lenard Jones was used for Van der Waals energy term. A sigmoid
description of the dielectric constant and the FCPAC partial atomic charges [22]
were used for the Coulomb energy. Last, the equation developed by Brasseur
[20] for inter and molecule/solvent hydrophobicity was used. All energy values
are in kcal/mol.
2.2. In vitro assays
2.2.1. Preparation of SUV
Small unilamellar vesicles were made of phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine
(PS), sphingomyelin (SM) and cholesterol (Chol) (30%: 30%: 2,5%: 10%: 5%:
22.5% respectively; w/w).
Lipids were diluted in chloroform/methanol (2/1 vol/vol). After evapora-
tion, the film was dried for 2 h before being hydrated with Tris buffer pH 7.4
(Tris–HCl 10 mM, NaCl 150 mM, EDTA 0.5% and NaN3 1 mM) incubated at
37 -C with stirring every 10 min. The solution was sonicated at 50W twice for
5 min. Particulate matters and residual multilamellar vesicles were discarded by
centrifugation at 2000g for 5 min. Final concentration of phospholipid was
determined by the method of Barlett [25].
2.2.2. Fusion of lipid phase
Lipid fusion is monitored by fluorescence measurement using the method
previously described by Hoekstra and Klappe [26]. R-18 (octadecyl rhodamine
B chloride) labelled SUV are mixed with unlabelled SUV. In the presence of a
fusogenic agent, an increase of fluorescence signal is observed due to the
dilution of R18 in lipid phase. Labelled and unlabelled liposomes (1:4w/w ratio)
and Ah29–42 peptide (different peptide/lipid molar ratio between 0.01 and
0.2) were mixed at room temperature and the fluorescence signal was recorded
(excitation wavelength at 560 nm and emission wavelength at 590 nm).
2.2.3. Leakage of liposomes
The release of a substance encapsulated in liposomes is followed by
fluorescence [27]. HPTS (8-aminonaphtalene-1,3,6-trisulfonic acid) and his
quencher DPX (p-xylylenebis[pyridinium] bromide) were both encapsulated in
the aqueous phase of liposomes. Liposomes were eluted on a Sephadex G75 to
remove HPTS and DPX from medium. The HTPS fluorescence was measured at
room temperature using excitation and emission wavelengths at 450 nm and 512
nm, respectively. Dequenching of released HPTS followed leakage. The
percentage of release is defined as Ft/Ftot x100, where Ft is the fluorescence
signal at t time and Ftot is the signal obtained after vesicle lysis with 0.5% Triton
X100.
2.3. Materials
All solvents came from Sigma (St. Louis, USA); ApoE and mutant
peptides were synthesized by SYNT:EM (Nimes, F); Ah29–42 peptide came
from Polypeptide (G) and was 80% pure. All peptides are N-acetylated and
C-amidated; lipids were from Lipid Products (Surrey, UK), Sigma (St. Louis,
Fig. 2. Evolution of the energy of inter and total (inter plus intra) molecule
interactions of the peptide 11 and Ah complex during the procedure of Monte
Carlo and angular dynamics. The procedure lasts for few minutes and does not
show significant energy decrease if continued over. Energies are calculated as
detailed in Materials and methods.
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Sigma Chemical (USA) and the spectrofluorimeter LS-50B from Perkin
Elmer (Norwalk, USA).
3. Results and discussion
The method is a multi-step procedure that can be summarized
as follows: First we choose a complex in which the target is in
interaction with a molecule. This molecule will become our lead
for modelling. If no model of interaction exists, we calculate one
based on experimental data describing the interaction of the
target with a molecule. The second step is the characterization of
the initial complex. This step is crucial because it will define
which residues andwhich type of energies are responsible for the
association. Then, residues for substitution are proposed for each
key position. Structures corresponding to all combinations of
mutations are constructed and tested for their interaction with the
target. After optimisation, the best complexes are selected on
calculated criteria (energy of interaction, covered surfaces. . .).
The method is here applied to the design of an anti helical form
of Ah peptide. The template complex is the calculated complex
between Ah C-terminal domain and ApoE270–287 amphipath-
ic helix.
3.1. Calculation of the template complex
We started from the molecular modelling approach by Lins
et al. [14] and used the 270–287 fragment of apolipoprotein E as
template for the design of an anti Ahpeptide. In a first step, we
calculated the best ApoE270–287 (EDMQRQWAGLVEKV-
QAAV) and Ah29–42 (GAIIGLMVGGVVIA) complex
using a hypermatrix procedure. 2.6106 relative positions
were explored and the structure with the lowest energy was
saved. Orientation of the two helices is antiparallel as
previously reported [14]. The role of hydrophobicity is major
in the complex as seen by comparing hydrophobic accessible
surface area of residues in the free peptides and in the complex.
Hydrophobic accessible surface area of the complex (1760 A˚2)
is 21% lower than the sum of hydrophobic accessible surface
area of the free peptides (2229 A˚2). In parallel, the hydrophilic
accessible surface area is almost unchanged in the complex as
compared to the free peptides. This indicates that formation ofFig. 1. Lost Accessible Surface Area (ASA) as a function of ApoE270–287
residues in the complex with Ah and alone (in %).the complex hides hydrophobic parts of both molecules. Those
results confirm those of Lins et al. [14] and clearly point
towards hydrophobicity as a key parameter for the complex
stability.
3.2. Identification of key residues
The ApoE270–287 residues in interaction with Ah were
characterized by analysis of accessible surface (Fig. 1). We
assumed that peptide residues of ApoE270–287 with less water-
accessible surface in the complex than in the free form were
implicated in the interaction. Those residues are located on the
same side of the ApoE helix: M272, W276, L279, V280 and
V283 and they have lost 18%, 65%, 15%, 34% and 19% of their
solvent accessibility in the complex, respectively. These residues
were selected for mutation by substitution.
3.3. Residues proposed for substitution
Two criteria were used to define which residues would be
used for substitution. First, in the template complex, most
residues are involved in apolar interactions, hence residues
proposed for substitutions had to be hydrophobic to keep the
initial character of the interaction.
Second, although the structure of Ah2942 is known to be
variable, its fusogenic activities are related to helix structure
properties. On the other hand, the ApoE270–287 is an
amphipathic helix structure in the whole protein. Hence,
substituted residues had to induce a high helix propensity for
the de novo peptide [28]. Based on these criteria, Met, Trp and
Leu were chosen. Despite its low propensity as helix inductor,
Val was also selected due to its high hydrophobicity and its
presence in the original peptide.
3.4. Mutant complex calculations and initial selection
Using the original ApoE–Ah complex, we tested the 1024
structures obtained by combinations of residue substitution for
M272, W276, L279, V280 and V283. All peptides were
Table 1
Sequences of ApoE mutants selected by the automatic procedure
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Mutants W.T. E D M Q R Q W A G L V E K V Q A A V
11 E D M Q R Q L A G V V E K V Q A A V
12 E D M Q R Q L A G L V E K W Q A A V
28 E D M Q R Q L A G M W E K V Q A A V
308 E D V Q R Q L A G L V E K V Q A A V
413 E D M Q R Q M A G L M E K M Q A A V
450 E D M Q R Q V A G M W E K V Q A A V
Mutated positions are in bold.
Residues are renumbered from 1 to 18.
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of a Monte Carlo procedure based on angular dynamics. A
primary selection was based on the minimization of the energy
of intra plus inter molecule interactions (Fig. 2).
Six complexes were selected which all have gained energy as
compared to the initial ApoE–Ah complex. Analysis of their
sequences (Table 1) shows that Met 3 of the original ApoE
peptide is frequently conserved, probably because of its side
chain flexibility which allows a high ability of interaction.
Conversely, Trp residue seems to be excluded from central
positions 7 and 10. Residues at the other positions are more
variable.
3.5. Final selection of peptides
In the previous steps, valence angles and bond lengths
were constant. Now, peptide geometry of complexes is
relaxed by a conjugate gradient procedure using HyperChem
that converged to 0.1 kcal/step. A close comparison of the 6
relaxed complexes was then carried out based on the analysis
of partner interactions (Ah and the mutant peptide) (Tables 2
and 3). If 6 complexes have a global gain of energy with
respect to the ApoE–Ah complex, only 3 have gained this
energy in the interaction between peptides (Table 2). These 3
complexes are with peptides 11, 12 and 413 and were thus
selected to go ahead.
From the three complexes, two types can be identified
according to the energy gain, either electrostatic gain
(complexes 12 and 413) or hydrophobic gain (complex
11).Table 2
Energy gain of the six primary-selected complexes (peptide/Ah29–42) by referenc
Ah partner y Etot_inter y MFP_inter y E VdW
Lenard Jones
Apo E 0.0 0.0 0.0
11 10.1 73.3 6.0
12 16.4 3.8 4.1
28 5.1 3.9 5.3
308 32.3 96.7 17.4
413 15.7 1.1 8.4
450 27.0 16.0 7.6
1st column gives the Ah partner name, other columns give the gain in several terms
sum of Van der Waals (Lenard Jones), electrostatic and intermolecular hydrophobici
force potential are calculated as described in Materials and methods. The hydrophobi
the last column and was used as an index of the complex solubility.Complex 11 gains 5 kcal/mol in the hydrophobicity ‘‘Epho
inter’’ as compared to the ApoE–Ah complex. It also shows a
significant gain in Mean Force Potential supporting that several
atoms have found favourable partners. The Ah surface initially
covered by ApoE is increased by 133 A˚2 further supporting a
good Ah-peptide 11 surface matching (Table 2, Fig. 3).
Main interest of complexes with peptides 413 and 12 results
from electrostatic gains and from a good matching of the two
peptides surface (+56 A˚2 more of Ah surface is covered by
peptide 12 as compared to ApoE, and +31 A˚2 more by peptide
413) (Table 2). The two peptides have linked their backbone to
enable the interaction of the N end of Ahwith the C end of the
two peptides (Fig. 3).
Reasons for pairing improvement are further analysed in
Table 3. In this table, the closest inter-peptide atomic interactions
are listed: the three first for the initial ApoE–Ah complex only,
the first one for the peptides 11 and 413 in complex with Ah.
This highlights the major role of W276 in the initial ApoE–Ah
complex. Tryptophan is a bulky hydrophobic residue hence its
role in binding is easy to understand. Its central position in the
ApoE peptide attracts apolar atoms of Ah but also keeps the rigid
helix away decreasing by this way the other residue binding
possibilities. Mutation of this tryptophan which was frequently
noticed in our peptides increases the peptide flexibility
(backbone kicking is observed) and enables a more complete
surface pairing. Hence, the terminal valine (V18) of peptides
(corresponding to V289 in the ApoE) becomes amajor partner of
Ah as do residues at positions 3 and 7.
3.6. Biophysical assay
The peptides 11 and 413 were synthesized, each represen-
tative of a different kind of complex.
3.6.1. Fusion of lipid phase
Ah29–42 induces liposome fusion ‘‘in vitro’’ [29]. This is
detected by dequenching of R18 fluorescence, a lipophilic
probe. In this study, we compared the inhibitory effect of
ApoE270–287 and of peptides 11 and 413 on liposome fusion
induced by Ah29–42. Neither ApoE270–287 fragment nor
mutants have self-fusogenic properties: none induces the fusion
of liposomes. By contrast, in the presence of Ah29–42e to the ApoE270–287/Ah29–42 complex
y E electrostatic y E pho
intermolecule
y E pho
solvent
y masked
ASA
0.0 0.0 0.0 0.0
0.9 5.0 18.5 133
20.7 0.1 22.4 56
1.3 1.1 46.6 27
9.0 23.8 93.1 116
27.3 3.3 104.8 31
4.5 23.8 151.2 22
of energy (kcal/mol) and the loss in solvent-accessible surface (A˚2). E tot is the
ty, the explicit values of which are detailed in the next columns. Values of mean
city contribution of the solvent-accessible surface of the complex is also given in
Fig. 3. Complexes of Ahwith ApoE, peptides 11 and 413. The green CPK view
is the Ah peptide whereas the stick structures are ApoE270–287, peptide 11
and peptide 413 as specified on the figure. The N side of Ah is up and the N
side of peptides ApoE, 11 and 413 are down.
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M. Decaffmeyer et al. / Biochimica et Biophysica Acta 1758 (2006) 320–327 325(peptide/lipid ratio of 0.4 (mol/mol)), the R18 fluorescence
rapidly increases indicating lipid destabilization and liposome
fusion. This signal stands for 100% Ah activity (Table 4) and
will be inhibited in case of Ah binding with the partner peptide
(ApoE, peptides 11 and 413). In the inhibition assays, we
assumed a 1/1 molar ratio between the Ah29–42 peptide and
the inhibitor peptide in agreement with the pairing hypothesis.
When the ApoE270–287 peptide is added to liposomes at the
same time as the Ah29–42 fragment, 11% decrease of the
fluorescence signal is observed indicating that the interaction
between the two peptides has slightly decreased the fusogenic
potential of Ah29–42 (Table 4). Those results are in agreement
with those of Pillot et al. [11]. When peptides 11 and 413 are
added, inhibition is more important (83% and 79%,
respectively) (Table 4). This suggests a more potent interac-
tions of peptides 11 and 413 with Ah29–42 than of ApoE with
Ah in agreement with our calculations.
3.6.2. Liposome leakage
We next checked that the R18 dye response was due to a true
perturbation of membranes and not only to its dilution in lipids
after vesicle aggregation. In order to assess the destabilization of
SUV membranes, HTPS and DPX were both trapped in
liposomes. In case of leakage, HTPS fluorescence will increase.
Peptides 11 and 413 induce no fluorescence increase when
added alone. In the presence of Ah29–42 (peptide/lipid molar
ratio of 0.4), the fluorescence of HTPS immediately increases
(28% of the maximal signal). In the presence of peptide 11 or
peptide 413 (at a 1:1 molar ratio), the Ah29–42 signal is close to
zero, 0% and 4%, respectively (Table 4). This suggests that both
peptides impair the membrane-destabilizing properties of
Ah29–42. The leakage signal remains close to zero when theTable 4
Lipid fusion and leakage induced by Ah29–42 and inhibitory effects of ApoE
WT, ApoE mutant 11 and ApoE mutant 413 monitored by fluorescence at room
temperature at a 1/1 peptide ratio
Peptides added
to the liposomes
% of fusion
after 15 min
% of leakage
after 15 min
Ah alone 100 28
Ah+ mutant 413 (R =1) 21 4
Ah+ mutant 11 (R =1) 17 0
Ah+ ApoE WT (R =1) 89 ND
Values are in % and are averages of values in the plateau of fluorescence
(between 10 and 15 min) of three different experiments.
M. Decaffmeyer et al. / Biochimica et Biophysica Acta 1758 (2006) 320–327326peptides (11 or 413)/Ah29–42 molar ratio are varied from 0.4 to
4. This is in agreement with the lipid fusion assays and the
modelling calculations.
4. General conclusions
The PepDesign algorithm is a rapid multi-steps procedure
based on algorithms that others and we have developed in the
past (Soft Levitt approach for the modulation of steric clashes
between atoms [21], hypermatrix for calculating the complex
structure [16], angular dynamics for the rapid optimisation of
the complex structure [20], Pex for the analysis and com-
parison of structures [17]). The major strength of the method is
in its insight in the mechanism of molecule interaction. In this
case, we designed a peptide able to bind to the hydrophobic
side of the helix structure of Ah29–42 because previous data
supported the hypothesis that hydrophobicity pattern of this
helix was involved in Ab fusogenic capacities. The mechan-
isms of interaction between carrier peptides and their cargoes
should go the other way round. The carrier should cover cargo
hydrophilic parts since they make hydrophobic complexes. The
biological process is inverse but the modelling protocol will
remain similar.
Actual capacities of molecular modelling are still a subject of
debates. We support the idea that real success in molecular
modelling strongly depend upon the pertinence of hypotheses
and the adequacy of empirical calculation approaches. Comput-
er-aided design of molecules has been used for many years but
often as side-support of experimental approaches. We here
suggest that in silico calculations can take a major part in
molecule-design processes. If it cannot replace experimental
assays it might valuate them by focusing them to a few selected
cases. Both experimental and theoretical approaches should gain
in that collaboration. The Molecular Recognition Theory has
allowed designing peptides that non-covalently bind proteins or
peptides. Campbell et al. [30], using the MIMETIC program
designed peptides which recognize fragments of HIV-1 reverse
transcriptase. Three of the ten peptides they designed were able
to inhibit reverse transcription in vitro. Using the same
algorithm, Shimomura et al. [31] designed complementary
peptides to thrombomodullin. This protein decreases the
formation of the thrombomodullin/thrombin complex implicat-
ed in the carboxypeptidase R activation. In that case, two of the
three computed peptides were efficient.
Recent progresses inmolecular modelling seem to result from
opportunities opened by increases in computer capacities, by
increases in the number of research in the domain and last but not
least by the demand urging from biotechnologies. As a
consequence, tremendous progresses have been made in the
last decade which are evidenced by the emergence of calculation
tools. PepDesign is one example. Many factors are combined for
PepDesign efficacy, three are major: first is Pex ([17]*). Pex
transforms PDB files of structures into worksheets compiling
large series of intra and inter molecule geometry and energy
parameters. This enables the rapid and complete comparison of
structures and leaves no place to subjective appreciations. Pex
were already used in several studies [18,19,32,33]. Second is theSoft Levitt’s equation for Van der Waals energy. Indeed, one
problem in computing structures is atomic steric clashes. A
single clash can result in a huge burst of energy which may hide
any real energy benefit farther in the structure. This can lead to
discard a structure which is however on the right way of folding.
Can steric clash be avoided in computing approaches? No
because all molecule movements proceed through discrete steps
in opposition with the continuity of natural movements. The
larger the steps, the most rapid the folding, the most frequent the
steric clashes. The smaller the steps, the longest the calculation
times, the less perturbing the steric clashes. Hence, a compro-
mise must be found. In its empirical description of Van derWaals
energy, M. Levitt introduced a limit value, i.e. a maximal
penality for a steric clash. This subterfuge is precious since it
allows a few hence transient atomic collisions on the way to a
final well-packed structure.
Another factor of PepDesign efficacy is angular dynamics.
Angular dynamics has been used for several years in protein
folding [20] and has been recently fully described for the de novo
design of a non-natural peptide [34]; its main advantage over
molecular dynamics is that large molecule movements can result
from small energy changes since movements are propagated on
the molecule torsion axes. In this study, minimization of peptide
complexes can be achieved within an hour in the best conditions.
This opens possibilities for comparative series of tests within
reasonable delay.
Combination of calculation procedures and of Pex analyses
of structures seem crucial to help peptide design at best. For
instance, in our assays of liposome leakage, we were unable to
efficiently distinguish between peptides 11 and 413. Hence, we
should have concluded that both peptides are equivalent.
However, the Pex analysis of Ah-peptide complexes leads to
the conclusion that peptide 11 should be more active than
peptide 413 when the entire Ah protein is concerned. Indeed
peptide 413 has part of its interaction with the N backbone end
of the Ah peptide. This fragment will not be accessible in the
complete protein as it is in the peptide. Thus, the modelling
approach suggests that only one of the three selected peptides,
peptide 11 will efficiently bind the Ah 1–42 protein.
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